Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-30T20:20:13.652Z Has data issue: false hasContentIssue false
  • English
  • Français

Immediate impact of healthcare-facility–onset Clostridium difficile laboratory-identified events reporting methodology change on standardized infection ratios

Published online by Cambridge University Press:  23 October 2018

Carlos E. Figueroa Castro ,
Louis Palen ,
Carrie Johnson ,
Mary Beth Graham ,
David Letzer ,
Nathan Ledeboer ,
Blake Buchan ,
Timothy Block ,
Heather Seliger  and
Siddhartha Singh
...Show all authors
Carlos E. Figueroa Castro
Affiliation:
Division of Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
Louis Palen
Affiliation:
Infection Prevention and Control Department, Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin
Carrie Johnson
Affiliation:
Infection Prevention and Control Department, Community Hospital Division, Milwaukee, Wisconsin
Mary Beth Graham
Affiliation:
Division of Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
David Letzer
Affiliation:
Infection Prevention and Control Department, Community Hospital Division, Milwaukee, Wisconsin
Nathan Ledeboer
Affiliation:
Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin
Blake Buchan
Affiliation:
Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin
Timothy Block
Affiliation:
Froedtert Health System, Milwaukee, Wisconsin.
Heather Seliger
Affiliation:
Infection Prevention and Control Department, Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin
Siddhartha Singh
Affiliation:
Division of Hospital Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
Elizabeth Behrens
Affiliation:
Froedtert Health System, Milwaukee, Wisconsin.
Susan Huerta
Affiliation:
Froedtert Health System, Milwaukee, Wisconsin.
L. Silvia Munoz-Price*
Affiliation:
Division of Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
*
Author for correspondence: L. Silvia Munoz-Price, MD, PhD, 8701 Watertown Plank Road, Milwaukee, WI 53226. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

In 2018, the Clostridium difficile LabID event methodology changed so that hospitals doing 2-step tests, nucleic acid amplification test (NAAT) plus enzyme immunofluorescence assay (EIA), had their adjustment modified to EIA-based tests, and only positive final tests (eg, EIA) were counted in the numerator. We report the immediate impact of this methodological change at 3 Milwaukee hospitals.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 39 , Issue 12 , December 2018 , pp. 1484 - 1486
Copyright
© 2018 by The Society for Healthcare Epidemiology of America. All rights reserved. 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Cite this article: Figueroa Castro CE et al. (2018). Immediate impact of healthcare-facility–onset Clostridium difficile laboratory-identified events reporting methodology change on standardized infection ratios. Infection Control & Hospital Epidemiology 2018, 39, 1484–1486. doi: 10.1017/ice.2018.241

References

1. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention website. http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Published 2013. Accessed June 30, 2016.Google Scholar
2. Multidrug-resistant organism and Clostridium difficile infection (MDRO/CDI) module. Centers for Disease Control and Prevention website. https://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf. Published January 2018. Accessed July 28, 2018.Google Scholar
3. Lessa, FC, Winston, LG, McDonald, LC. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:2369–2370.Google Scholar
4. Humphries, RM, Uslan, DZ, Rubin, Z. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J Clin Microbiol 2013;51:869–873.Google Scholar
5. Guerrero, DM, Chou, C, Jury, LA, Nerandzic, MM, Cadnum, JC, Donskey, CJ. Clinical and infection control implications of Clostridium difficile infection with negative enzyme immunoassay for toxin. Clin Infect Dis 2011;53:287–290.Google Scholar
6. Polage, CR, Gyorke, CE, Kennedy, MA, et al. Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era. JAMA Intern Med 2015;175:1792–1801.Google Scholar
7. McDonald, LC, Gerding, DN, Johnson, S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:987–994.Google Scholar
8. Cannon, CM, Musuuza, JS, Barker, AK, et al. Risk of Clostridium difficile infection in hematology-oncology patients colonized with toxigenic C. difficile . Infect Control Hosp Epidemiol 2017;38:718–720.Google Scholar
9. Jain, T, Croswell, C, Urday-Cornejo, V, et al. Clostridium Difficile colonization in hematopoietic stem cell transplant recipients: a prospective study of the epidemiology and outcomes involving toxigenic and nontoxigenic strains. Biol Blood Marrow Transpl 2016;22:157–163.Google Scholar